| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Chim C Lang | |
| Jacqueline Howie | |||
| John R Petrie | |||
| Aaron K F Wong | |||
| P2860 | cites work | Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. | Q44470244 |
| Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart | Q44532391 | ||
| AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells | Q44538214 | ||
| Adiponectin stimulates production of nitric oxide in vascular endothelial cells. | Q44565932 | ||
| AICAR stimulates adiponectin and inhibits cytokines in adipose tissue | Q44807015 | ||
| Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? | Q44816749 | ||
| Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte | Q44907827 | ||
| AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation | Q44985604 | ||
| Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade | Q21245891 | ||
| Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes | Q22241283 | ||
| Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 | ||
| Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms | Q22241963 | ||
| Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration | Q22241965 | ||
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Metformin | Q22250907 | ||
| Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia | Q24290495 | ||
| Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis | Q24291256 | ||
| Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy | Q24292259 | ||
| Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate | Q24296690 | ||
| Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase | Q24309462 | ||
| LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1 | Q24310603 | ||
| CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations | Q24614590 | ||
| The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress | Q24633606 | ||
| Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha | Q24793384 | ||
| Nitric oxide: physiology, pathophysiology, and pharmacology | Q26778243 | ||
| Contraction-Induced Fatty Acid Translocase/CD36 Translocation in Rat Cardiac Myocytes Is Mediated Through AMP-Activated Protein Kinase Signaling | Q27832095 | ||
| A serine/threonine kinase gene defective in Peutz-Jeghers syndrome | Q28119198 | ||
| Identification of a gene responsible for familial Wolff-Parkinson-White syndrome | Q28201949 | ||
| Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase | Q28215845 | ||
| AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling | Q28216932 | ||
| Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis | Q28218978 | ||
| Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke | Q28240112 | ||
| AMP-activated protein kinase plays a role in the control of food intake | Q28240521 | ||
| AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus | Q28254114 | ||
| Reversible modulation of the activities of both liver microsomal hydroxymethylglutaryl coenzyme A reductase and its inactivating enzyme. Evidence for regulation by phosphorylation-dephosphorylation | Q28271672 | ||
| Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase | Q28283715 | ||
| Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase | Q28574062 | ||
| Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart | Q28574917 | ||
| LKB1 is the upstream kinase in the AMP-activated protein kinase cascade | Q28610414 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain | Q29615210 | ||
| An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) | Q29615693 | ||
| Leptin and the regulation of body weight in mammals | Q29615976 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 | ||
| Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history | Q33152428 | ||
| Functional analysis of mutations in the gamma 2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. | Q33184967 | ||
| Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome | Q33229028 | ||
| The role of TNFalpha and TNF receptors in obesity and insulin resistance | Q33680471 | ||
| Adiponectin-mediated modulation of hypertrophic signals in the heart | Q33688678 | ||
| Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms | Q33688706 | ||
| Molecular characterization of the AMP-activated protein kinase and its role in cellular metabolism. | Q41693724 | ||
| AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production | Q42269153 | ||
| Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo | Q42455836 | ||
| Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. | Q42476103 | ||
| Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 expression on human endothelial cells | Q42476708 | ||
| Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. | Q43596018 | ||
| Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy | Q43753479 | ||
| Energy substrate utilization by isolated working hearts from newborn rabbits | Q44000073 | ||
| Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice | Q44007043 | ||
| Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome | Q44043225 | ||
| Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes | Q44086594 | ||
| AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats | Q44155454 | ||
| Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase | Q44453273 | ||
| Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells | Q44468960 | ||
| Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease | Q45213515 | ||
| Dual mechanisms regulating AMPK kinase action in the ischemic heart. | Q45226539 | ||
| Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study | Q45256257 | ||
| Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism | Q45281571 | ||
| Statins activate AMP-activated protein kinase in vitro and in vivo | Q46230916 | ||
| AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome | Q46432574 | ||
| Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism | Q46502051 | ||
| Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration | Q46591896 | ||
| Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms | Q46601702 | ||
| Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes | Q46680292 | ||
| Improved clinical outcomes associated with metformin in patients with diabetes and heart failure | Q46722279 | ||
| Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. | Q46731659 | ||
| Role of AMP-activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle | Q46764341 | ||
| Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide | Q46789134 | ||
| Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling | Q46847423 | ||
| Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase | Q46917092 | ||
| AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. | Q46952844 | ||
| Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. | Q46966126 | ||
| Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis | Q46973117 | ||
| Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. | Q47866453 | ||
| Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats | Q48207714 | ||
| Plasma fatty acid levels in infants and adults after myocardial ischemia. | Q51630314 | ||
| Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. | Q52541795 | ||
| Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. | Q53361960 | ||
| Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol | Q68671948 | ||
| Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation | Q69493948 | ||
| A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis | Q69907652 | ||
| Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo | Q73012623 | ||
| Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice | Q73048909 | ||
| AMP-activated protein kinase phosphorylation of endothelial NO synthase | Q74456171 | ||
| Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy | Q77363631 | ||
| Effect of AMPK activation on muscle glucose metabolism in conscious rats | Q77755573 | ||
| A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes | Q79792326 | ||
| Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease | Q80519509 | ||
| Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. | Q33821960 | ||
| Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. | Q33929661 | ||
| Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance | Q33941406 | ||
| Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. | Q34012881 | ||
| Lipotoxic diseases | Q34111950 | ||
| AMPK beta subunit targets metabolic stress sensing to glycogen | Q34196956 | ||
| The structure of a domain common to archaebacteria and the homocystinuria disease protein | Q34415436 | ||
| Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation | Q34416242 | ||
| AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle | Q34452979 | ||
| Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. | Q34506457 | ||
| The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. | Q34522920 | ||
| The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism | Q34525699 | ||
| 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. | Q34629958 | ||
| Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis | Q34634794 | ||
| AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression | Q34764173 | ||
| Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes | Q35053050 | ||
| Neuroprotection mediated by changes in the endothelial actin cytoskeleton. | Q35128290 | ||
| Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. | Q35213694 | ||
| Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). | Q35566946 | ||
| Prevalence of the metabolic syndrome in US populations | Q35781474 | ||
| Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence | Q36177005 | ||
| Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. | Q36248613 | ||
| Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders | Q36462591 | ||
| AMPK alterations in cardiac physiology and pathology: enemy or ally? | Q36475855 | ||
| Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease | Q36667186 | ||
| Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample | Q36834958 | ||
| Preprocedural statin therapy in percutaneous coronary intervention | Q36915760 | ||
| Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials | Q36955489 | ||
| Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1 | Q37111703 | ||
| AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury | Q37286204 | ||
| 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice | Q38292086 | ||
| Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome | Q38312576 | ||
| Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth | Q40105523 | ||
| Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation | Q40403270 | ||
| Interleukin-6 induces cellular insulin resistance in hepatocytes | Q40687381 | ||
| Free fatty acid metabolism during myocardial ischemia and reperfusion | Q41358557 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 2.5 Generic | Q19113746 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | peptide | Q172847 |
| enzyme | Q8047 | ||
| cardiovascular disease | Q389735 | ||
| metabolic syndrome | Q657193 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 607-620 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Clinical Science | Q372419 |
| P1476 | title | AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease | |
| P478 | volume | 116 |
| Q38222605 | 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5'-Monophosphate (AICAR), a Highly Conserved Purine Intermediate with Multiple Effects |
| Q40934279 | 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside-attenuates LPS/D-Gal-induced acute hepatitis in mice |
| Q36815297 | A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats |
| Q39801353 | A novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection. |
| Q33932744 | A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. |
| Q41684518 | AICAR Administration Attenuates Hemorrhagic Hyperglycemia and Lowers Oxygen Debt in Anesthetized Male Rabbits |
| Q37108786 | AICAR reduces the collagen-stimulated secretion of PDGF-AB and release of soluble CD40 ligand from human platelets: Suppression of HSP27 phosphorylation via p44/p42 MAP kinase. |
| Q37856788 | AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan |
| Q37671250 | AMP-activated protein kinase: a stress-responsive kinase with implications for cardiovascular disease. |
| Q37951443 | AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart |
| Q42879466 | AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE-/- mice |
| Q53372149 | AMPK activation reduces vascular permeability and airway inflammation by regulating HIF/VEGFA pathway in a murine model of toluene diisocyanate-induced asthma. |
| Q41989991 | AMPK activator AICAR ameliorates ischaemia reperfusion injury in the rat kidney |
| Q47369070 | AMPK and cardiac remodelling. |
| Q37812782 | AMPK and vasculoprotection |
| Q35920708 | AMPK enhances insulin-stimulated GLUT4 regulation via lowering membrane cholesterol. |
| Q92623635 | AMPK: a balancer of the renin-angiotensin system |
| Q60921233 | AMPK: a therapeutic target of heart failure-not only metabolism regulation |
| Q45013474 | Activation of Adenosine Monophosphate-Activated Protein Kinase Is an Additional Mechanism That Participates in Mediating Inhibitory Actions of Prostaglandin F2Alpha in Mature, but Not Developing, Bovine Corpora Lutea |
| Q38450680 | Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. |
| Q44418878 | An Update on AMPK in Hydrogen Sulfide Pharmacology |
| Q34189477 | Anti-inflammatory nutrition as a pharmacological approach to treat obesity |
| Q51750481 | Beneficial effect of the bioflavonoid quercetin on cholecystokinin-induced mitochondrial dysfunction in isolated rat pancreatic acinar cells. |
| Q37052961 | CHIP protects against cardiac pressure overload through regulation of AMPK. |
| Q36051510 | Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis |
| Q56535621 | Cathepsins: Proteases that are vital for survival but can also be fatal |
| Q28081013 | Cellular and molecular biology of aging endothelial cells |
| Q91851182 | Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai |
| Q36251554 | Defining the Molecular Nexus of Cancer, Type 2 Diabetes and Cardiovascular Disease |
| Q49247394 | Dioxygen and Metabolism; Dangerous Liaisons in Cardiac Function and Disease |
| Q64949572 | Drug repurposing in alternative medicine: herbal digestive Sochehwan exerts multifaceted effects against metabolic syndrome. |
| Q54616760 | Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats. |
| Q35838049 | Fatty Acid Oxidation and Cardiovascular Risk during Menopause: A Mitochondrial Connection? |
| Q43091072 | Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. |
| Q34855692 | Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer |
| Q54440549 | HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. |
| Q83749924 | Implication of AMP-activated protein kinase in transient receptor potential vanilloid type 1-mediated activation of endothelial nitric oxide synthase |
| Q36185141 | Insulin down-regulates the expression of ubiquitin E3 ligases partially by inhibiting the activity and expression of AMP-activated protein kinase in L6 myotubes |
| Q36821424 | Insulin resistance: metabolic mechanisms and consequences in the heart. |
| Q37636514 | Interactome analysis of AMP-activated protein kinase (AMPK)-α1 and -β1 in INS-1 pancreatic beta-cells by affinity purification-mass spectrometry |
| Q57822222 | Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease |
| Q36820974 | Metabolic switching and fuel choice during T-cell differentiation and memory development |
| Q55032055 | Metformin alleviates vascular calcification induced by vitamin D3 plus nicotine in rats via the AMPK pathway. |
| Q35114963 | Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis |
| Q51373277 | Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. |
| Q35796984 | Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. |
| Q33793434 | Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes |
| Q21134128 | Micro-RNA-195 and -451 regulate the LKB1/AMPK signaling axis by targeting MO25 |
| Q38829598 | New synthetic AICAR derivatives with enhanced AMPK and ACC activation |
| Q37927098 | Nitric oxide: orchestrator of endothelium-dependent responses |
| Q37786170 | Novel regulators and drug targets of cardiac hypertrophy |
| Q36227345 | Oestrogen receptors interact with the α-catalytic subunit of AMP-activated protein kinase |
| Q58579343 | Pesticides as the drivers of neuropsychotic diseases, cancers, and teratogenicity among agro-workers as well as general public |
| Q37801370 | Pharmacological treatment of obesity in children and adolescents: current status and perspectives. |
| Q37817710 | Physical activity as the main therapeutic tool for metabolic syndrome in childhood |
| Q35613008 | Post-treatment with the combination of 5-aminoimidazole-4-carboxyamide ribonucleoside and carnitine improves renal function after ischemia/reperfusion injury |
| Q30234943 | Progress of small molecular inhibitors in the development of anti-influenza virus agents |
| Q34214717 | Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198) |
| Q38377369 | Quantitative cardiac phosphoproteomics profiling during ischemia-reperfusion in an immature swine model |
| Q34756301 | Regulation of AMPK by the ubiquitin proteasome system |
| Q34998025 | Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways |
| Q38298547 | Screening methods for AMP-activated protein kinase modulators: a patent review |
| Q47711349 | Snail/beta-catenin signaling protects breast cancer cells from hypoxia attack |
| Q36329814 | Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin-binding protein-dependent reduction of β-catenin |
| Q59133335 | Solid-Phase Synthesis of a New Diphosphate 5-Aminoimidazole-4-carboxamide Riboside (AICAR) Derivative and Studies toward Cyclic AICAR Diphosphate Ribose |
| Q27694733 | Targeting myocardial substrate metabolism in heart failure: potential for new therapies |
| Q37400658 | The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling |
| Q53101458 | The Effects of Pycnogenol® as Add-on Drug to Metformin Therapy in Diabetic Rats. |
| Q89604720 | The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity |
| Q36031170 | The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese |
| Q28080686 | The role of Fatty Acid oxidation in the metabolic reprograming of activated t-cells |
| Q26748610 | The signaling involving in autophagy machinery in keratinocytes and therapeutic approaches for skin diseases |
| Q28534586 | Thiopental inhibits global protein synthesis by repression of eukaryotic elongation factor 2 and protects from hypoxic neuronal cell death |
| Q34969926 | Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC. |
| Q33884299 | To eat or not to eat: the effect of AICAR on food intake regulation in yellow-bellied marmots (Marmota flaviventris) |
| Q53242482 | Transient energy deficit induced by exercise increases 24-h fat oxidation in young trained men. |
| Q58447602 | Type 2 diabetes mellitus |
Search more.